Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Royalty Pharma ( (RPRX) ) has issued an update.
On December 19, 2025, Cytokinetics announced U.S. FDA approval of MYQORZO (aficamten), a cardiac myosin inhibitor indicated for adult patients with symptomatic obstructive hypertrophic cardiomyopathy, triggering economic benefits to Royalty Pharma under prior funding agreements. Royalty Pharma is entitled to a tiered royalty on MYQORZO sales—4.5% on sales up to $5 billion and 1% above that threshold—and has provided Cytokinetics with up to $450 million in long-term and launch capital related to the drug, of which $275 million has been drawn and $20 million repaid as of September 30, 2025, with total repayments to Royalty Pharma expected to reach 1.9 times the amounts drawn over 10 years, including up to an additional $175 million that Cytokinetics can access following approval, reinforcing Royalty Pharma’s future cash flow visibility and exposure to a newly approved cardiovascular therapy.
The most recent analyst rating on (RPRX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Royalty Pharma stock, see the RPRX Stock Forecast page.
Spark’s Take on RPRX Stock
According to Spark, TipRanks’ AI Analyst, RPRX is a Outperform.
Royalty Pharma’s strong financial performance and positive earnings call are the most significant factors driving the stock’s score. The company’s robust profitability, strategic acquisitions, and raised guidance underscore its growth potential. While technical analysis and valuation suggest a stable outlook, the strategic corporate event further enhances its financial position. Overall, the stock is well-positioned for future growth in the biotechnology industry.
To see Spark’s full report on RPRX stock, click here.
More about Royalty Pharma
Royalty Pharma operates in the biopharmaceutical finance and royalty acquisition industry, providing long-term and launch capital to drug developers in exchange for royalty interests tied to future product sales, thereby gaining exposure to commercial performance without directly marketing or manufacturing medicines.
Average Trading Volume: 3,948,191
Technical Sentiment Signal: Buy
Current Market Cap: $22.28B
For detailed information about RPRX stock, go to TipRanks’ Stock Analysis page.